主科別

過敏風濕免疫科

關注科別

過敏風濕免疫科

證照

‧國際臨床骨質密度診斷協會(ISCD)認證會員(Certified Clinical Densitometry Clinician)
‧美國臨床研究專業協會(ACRP)認證會員(Certified Physician Investigator, ICH-I-0306-006)
‧美國風濕病學院(ACR) 院士
‧美國家庭醫學學院(AAFP) 會員
‧美國自然醫學會 (ANMA) 會員暨專科醫師(Naturopathy Doctor)
‧國際僵直性脊椎炎研究組織(ASIF, ASAS)會員
‧中華民國免疫學會監事，中華民國風濕病醫學會監事
‧中華民國家庭醫學醫學會，並任繼續教育委員會及資訊委員會委員。
‧中華民國風濕病醫學會，並任病人教育委員會主席、公關委員會及資訊委員會委員。
‧內科醫學會、過敏免疫醫學會、超音波醫學會、預防醫學會、老年醫學會、健診學會、中西整合醫學會會員。

2010.10 FDA GCP SITE INSPECTION PASSED
2010中山醫學大學優秀論文獎
2009中華民國風濕病醫學會優秀論文獎
2007中山醫學大學學生票選優良教師
2006中山醫學大學附設醫院教學優良獎
2001嘉義榮民醫院優良醫師

經歷

‧台中榮總家庭醫學科醫師
‧高雄榮總過敏免疫風濕科總醫師
‧過敏免疫科、風濕科、內科、家醫科、中西結合專科醫師
‧嘉義榮民醫院家庭醫學科主任
‧中華民國僵直性脊椎炎關懷協會第二屆理事長
‧中山醫學大學附設醫院人體試驗委員會主任委員
‧行政院衛生署人體試驗/研究倫理委員會訪查委員

訓練：
中正大學企管班，行銷管理學分班。
中國醫藥學院中醫學分班。榮總傳統醫學中心針灸班。
中醫藥科學化暨全球智材及管理策略人才培訓班

職位

‧中山醫學大學附設醫院過敏免疫風濕科主任；中藥臨床試驗中心主任
‧中山醫學大學醫學研究所副教授
‧中國醫藥大學中西醫結合研究所兼任副教授

專長

僵直性脊椎炎 風濕病 過敏 免疫 痛風 臨床試驗 整合醫學

著作

期刊編審：
Editor, International Journal of Rheumatology
Reviewer, Annals of Rheumatic Diseases
Reviewer, Journal of Rheumatology
Reviewer, Clinical Rheumatology
Reviewer, Formosan Journal of Rheumatology

代表性著作
1.James Cheng-Chung Wei. A randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of Danshen (Salvia miltiorrhiza) as add-on anti-hypertensive therapy in Taiwanese patients with uncontrolled hypertension. Phytotherapy Research 2011 accepted. (SCI, Impact factor: 1.878；Ranking: 25/54；46%)
2.Huang CH, Wong RH, Wei JC, Tsay MD, Chen WC, Chen HY, Shih WT, Chiou SP, Tu YC, Lee HS. Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology (Oxford). 2011 Jul 26. (SCI, Impact factor: 4.312；Ranking: 9/22；40%；Score 3x3x51=9)
3.James Cheng-Chung Wei. Association of ORAI1 haplotypes with the Risk of HLA-B27 positive Ankylosing. Spondylitis. PLoS One. 2011;6(6):e20426. (SCI, Impact factor: 4.351；Ranking: 10/76；13%)
4.Shih-Shen Chou Lin, Lengsu William Chin, Pei-Chun Chao, Ya-Yun Lai, Long-Yau Lin, Ming-Yung Chou, Ming-Chih Chou, James Cheng-Chung Wei and Chi-Chiang Yang. In Vivo Th1 and Th2 Cytokine Modulation Effects of Rhodiola rosea Standardised Solution and its Major Constituent, Salidroside. Phytotherapy Research online: 11 MAR 2011 | DOI: 10.1002/ptr.3451(SCI, Impact factor: 1.878；Ranking: 25/54；46%)
5.Cherng JM, Tsai KD, Perng DS, Wang JS, Wei CC, Lin JC. Diallyl sulfide protects against ultraviolet B-induced skin cancers in SKH-1 hairless mouse: analysis of early molecular events in carcinogenesis. Photodermatol Photoimmunol Photomed. 2011 Jun;27(3):138-146. (SCI, Impact factor: 1.6047；Ranking: 24/48；50%)
6.Chun Huang Huang, James Cheng Chung Wei, Pei Shan Hung, Li Jie Shiu, Ming Dow Tsay, Ruey Hong Wong and Hong Shen Lee. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. Rheumatology 2011;50:359–365 (SCI, Impact factor: 4.312；Ranking: 9/22；40%；Score 3x3x5=45)
7.Y-C Huang and JC-C Wei. Plasma pyridoxal 50-phosphate is not correlated with hemoglobin during pyridoxine supplementation in patients with rheumatoid arthritis. European Journal of Clinical Nutrition (2010), 1–2. (SCI, Impact factor: 3.072；Ranking:17/66=26%; Score 1x3x4=12)
8.Chou CT, Tsai CY, Liang TH, Chang TM, Lai CH, Wei CC, Chen KH, Lin SC, Yu CL, Liou LB, Luo SF, Lee CS, Hsue YT, Huang CM, Chen JH, Lai NS, Cheng HH, Cheng TT, Lai HM, Tsai WC, Yen JH, Lu LY, Chang CP. Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis. Mod Rheumatol. 2010 Aug 4.
9.Huang SC, Wei JC, Wu DJ, Huang YC. Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. European Journal of Clinical Nutrition (2010) 64, 1007–1013 (SCI, Impact factor: 3.072；Ranking:17/66=26%; Score 3x3x4=36)
10.Consuelo Romero-Sanchez, Hsi-Kai Tsou, Ming-Shiou Jan, Ruey-Hong Wong, I-Chang Chang, John London, Rafael Valle-Onate, Hwee Siew Howe, David Yu, Bernard P. Leung, James Cheng-Chung Wei. Serum monocyte chemotactic protein-1 concentrations distinguish patients with ankylosing spondylitis from patients with mechanical low back pain. Journal of Spinal Disorders & Techniques 2011 May;24(3):202-7.. (SCI, Impact factor: 1.333；Ranking: 29/61；47%; Score 3x3x5=45) *Correspondence
11.張慧瑾,魏正宗.中依要點及數位典藏現況探討 台灣中醫醫學雜誌2010;9(1):31-42.
12.Hui-Fen Liao, Min-Chi Lu, Hon-Chou Chang, Cheng-Chung Wei, Chih-Hsiung Kao, Zong-Huei Chen, Chin-Chin Huang and Ching Li. Effects of Herbal Medicinal Formulas on Suppressing Viral Replication and Modulating Immune Responses. The American 1 Journal of Chinese Medicine 2010 Oct; Vol. 38, No. 1, 173-190(SCI)
13.Yi-Ling Chen, MD, Ming-Shiou Jan, PhD, Ming-Yung Lee, PhD, Li-Jie Shiu, Bor-Leun Chiang, James Cheng-Chung Wei. Efficacy and immunomodulation of sterols/Sterolins in patients with allergic rhinitis: A randomized double blind placebo-controlled clinical trial. Formosan Journal of Rheumatology 2009;23(2)72-81. *Correspondence (Score 3x0.5x5=7.5)
14.Jieruo Gu, Yu-Ling Wei, James C. C. Wei, Feng Huang, Ming-Shiou Jan, Michael Centola, Mark B. Frank, and David Yu. Identification of RGS1 as a Candidate Biomarker for Undifferentiated Spondylarthritis by Genome-Wide Expression Profiling and Real-Time Polymerase Chain Reaction. ARTHRITIS & RHEUMATISM Vol. 60, No. 11, November 2009, pp 3269–3279. (Drs. Gu and James C. C. Wei and Ms Yu-Ling Wei contributed equally) (SCI, Impact factor: 6.787；Ranking: 2/22；9%; Score 3x7.5x5=112.5)
15.James Cheng-Chung Wei, Hong-Shen Lee, Wei-Chiao Chen, Li-Jie Shiu, Shun-Fa Yang, and Ruey-Hong Wong. Genetic Polymorphisms of the Matrix Metalloproteinase-3 (MMP-3) and Tissue Inhibitors of Matrix Metalloproteinases-1 (TIMP-1) Modulate the Development of Ankylosing Spondylitis. Annals of the Rheumatic Diseases. 2009;68:1781–1786. doi:10.1136/ard.2008.099481 (SCI, Impact factor: 7.188；Ranking: 1/22；5%; Score 3x7.5x5=112.5)
16.The effectiveness of exercise therapy for ankylosing spondylitis. Ching-Yi WANG, Pin-Yen CHIANG, Hong-Shen LEE and James Cheng-Chung WEI. International Journal of Rheumatic Diseases 2009; 12: 207–210*Correspondence(Score 2x0.5x5=5)
17.Rudwaleit M, van der Heijde D,Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H , Sørensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The Development of Assessment of SpondyloArthritis international Society (ASAS) Classification Criteria for Axial Spondyloarthritis (Part II): Validation and Final Selection. Annals of the Rheumatic Diseases 2009 doi:10.1136/ ard.2009.108233; ISSN 003-4967(SCI, Impact factor: 7.188；Ranking: 1/22；5%; Score 3x7.5x0.5=11.25)
18.Soo-Ray Wang; Stephen Hou; Amy Wang; Yu-Jun Chang; Cheng-Tzu Liu; Gregory J.Tsay; Chung-Cheng Wei. The Significance of Arginase I Administration on the Survival of Mice Bearing NS-1 Myeloma Cells. Journal of Surgical Research 151,28-32 ; ISSN 0022-4804(2009) (SCI, Impact factor: 1.875；Ranking: 87/148；59%； Score 3x3x0.5=4.5)
19.Lin PT, Cheng CH, Wei JC, Huang YC. Low plasma pyridoxal 5′-phosphate concentration and MTHFR 677C → T genotypes are associated with increased risk of hypertension. Int J Vitam Nutr Res. 2008 Jan;78(1):33-40. ISSN 0300-9831 (SCI, Impact factor: 0.917；Ranking: 29/59；49%； Score 3x3x1=9)
20.Chen-Tung Yu; Wenlung Li; Ching-Sung Wang; Chien-Wei Liu; Chia-Chi Lo; Wei, J.C.-C. Biomechanical Analysis of Tibial Insert Under Varus Tilt After Medial Unicompartmental Knee Arthroplasy. Bioinformatics and Biomedical Engineering, 2008:1225 – 1228. Digital Object Identifier 10.1109/ICBBE.2008.634 (EI)
21.Chen-Tung Yu, Jui-Kei Wu, Chiung-Chiung Chang, Chiu-Liang Chen, James Cheng-Chung Wei*. Early callus formation in human hip fracture treated with internal fixation and teriparatide. The Journal of Rheumatology. 2008 Oct;35(10):2082-3 ; ISSN 0315-1624(SCI, Impact factor: 3.282；Ranking: 9/22；41%; Score 1x4x5=20)*Correspondence
22.Chien-Ming Chen, James Cheng-Chung Wei, Tzu-Ying Huang. Mesencephalic bilateral horizontal gaze palsies.Neurology. 2008 Sep 23;71(13):1039. ; ISSN 0028-3878 (SCI, Impact factor:7.043；Ranking:4/156；2%; Score 1x7.043x3=21)
23.Wei, James Cheng-Chung; Su, Yi-Chang; Chang, Hung-Chou; Jan, Ming-Shiou; Wong, Ruey-Hong; Chou, Chung-Tei. Patient Attitudes Toward Western Medicine and the Future of Chinese Medicine for Spondyloarthritis. Current Rheumatology Reviews, Volume 4, Number 2, May 2008 , pp. 120-123(4).
24.PH Huang, YH Liao, CC Wei, YH Tseng, JC Ho, TF Tsai. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. Journal of the European Academy of Dermatology and Venereology. 2008; ISSN 0926-9959. (SCI, Impact factor:2.276；Ranking: 30/43；70%; Score 3x2x1=6)
25.Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ. Serum reactivity against Borrelia burgdorferi OspA in patients with rheumatoid arthritis. Clinical and Vaccine Immunology. 2007 Nov;14(11):1437-41. ; ISSN 1556-6811.(SCI, Impact factor:2.237；Ranking: 28/121；23.9%; Score 3x4x0.5=6)
26.廖俊正 廖妙淯 陳順天 魏正宗. Behcet’s disease.當代醫學2007. 34(5) 394-8.
27.James Cheng-Chung Wei, Ruey-Hong Wong,Jun-Huang Huang, Chen-Tung Yu, Chung-Tei Chou, Ming-Shiou Jan, Gregory J. Tsay, Ming-Chih Chou, Hong-Shen Lee. Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clinical Rheumatology (2007) 26:1685–1691; ISSN 0770-3198. (SCI, Impact factor: 1.559；Ranking: 8/22；36%; Score 3x4x5=60)
28.Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK, Lee HS, Chou CT, Tsay G, Chou MC. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol. 2007 May;26(5):739-42. ; ISSN 0770-3198. (SCI, Impact factor: 1.559；Ranking: 8/22；36%；Score 3x4x5=60)
29.Lina Wang, Tzu-Hsin Tsai, Chien-Fu Huang, Mei-Shang Ho, Ding-Bang Lin, Yung-Chyuan Ho,Shih-Shen Lin, James Cheng-Chung Wei, Ming-Chih Chou, and Chi-Chiang Yang. Utilizing Self-Prepared ELISA Plates for a Cross-Population Study of Different Anti-HBe IgG Subclass Profiles. Journal of Medical Virology 79:495–502 (2007) ; ISSN 0146-6615. (SCI, Impact factor: 2.576；Ranking: 14/27；52%；Score 3x3x0.5=4.5)
30.Tsai JH, Hsu CS, Tsai CH, Su JM, Liu YT, Cheng MH, Wei JC, Chen FL, Yang CC. Relationship between viral factors, axillary lymph node status and survival in breast cancer. J Cancer Res Clin Oncol. 2007 Jan;133(1):13-21. (SCI, Impact factor: 2.217；Ranking: 81/141；57%；Score 3x1x0.5=1.5)
31.James Cheng-Chung Wei, Lan JL, Chen DY, Chung-Tei Chou. Experience of antitumor necrosis factor-α therapies in Taiwan. APLAR Rheumatology 2006;9:161-4.
32.Chou CT, Timms AE, Wei JC, Tsai WC, Wordsworth BP, Brown MA. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Annals of the Rheumatic Disease. 2006 Aug;65(8):1106-9; ISSN 0003-4967. (SCI, Impact factor: 7.188；Ranking: 1/22；5%；Score 3x7.188x1=21.56)
33.Tsai TH, Huang CF, Wei JC, Ho MS, Wang L, Tsai WY, Lin CC, Xu FL, Yang CC.Study of IgG subclass profiles of anti-HBs in populations with different HBV infection status.Viral Immunol. 2006 Summer;19(2):277-84; ISSN 0882-8245. (SCI, Impact factor: 1.949；Ranking: 21/27；78%；Score 3x2x1=6)
34.Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford). 2005;45(4):414-20; ISSN 1462-0324. (SCI, Impact factor: 4.312；Ranking: 7/22；31%；Score 3x4x0.5=6)
35.Yu-Yen Yang, Chien-Fu Huang, James Cheng-Chung Wei, Mei-Shang Ho, Lina Wang, Shyh-Jye Lin, Wei-Yu Tsai, Chien-Chou Lin, Fangling Xu, and Chi-Chiang Yang. The Study of IgG Subclass Profiles of Anti-HBc in Populations with Different Status of HBV Infection. Cellular & Molecular Immunology. 2005;2(5):393-398.
36.G. C.-L. Chi, F.-S. Hsu, C.-C. Yang, and J. C. Wei*. Scleroderma and failed response to alefacept . Rheumatology 2005; 44(10): 1328-30; ISSN 1462-0324. (SCI, Impact factor: 4.312；Ranking: 19/22；86%；Score 3x1x5=15) *Correspondence
37.James Cheng-Chung Wei. Evidence-Based Medicine in the Treatment of Psoriasis and Psoriatic Arthritis. J Rheumatol ROC,2005 ; 2 : 1-5.
38.C. T. Chou, K. C. Lin, J. C. C. Wei, W. C. Tsai, H. H. Ho, C. M. Hwang, J. M. Cherng, C. M. Hsu and D. T. Y. Yu. Study of undifferentiated spondyloarthropathy among first-degree relatives of ankylosing spondylitis probands. Rheumatology 2005 44(5):662-665; ISSN 1462-0324. (SCI, Impact factor: 4.312；Ranking: 9/22；40%；Score 3x1x5=15)
39.魏正宗. 僵直性脊椎炎之中西醫治療. 中西整合醫學雜誌2004;6(1):59~68,2004
40.Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 2004;43(7):839-42; ISSN1462-0324. (SCI, Impact factor: 4.312；Ranking: 19/22；86%；Score 3x1x5=15)
41.J.C-C. Wei, T.W. Chan, H-S. Lin, F. Huang, C-T. Chou. 2003/12. Thalidomide for Severe Refractory Ankylosing Spondylitis. Journal of Rheumatology 2003;30(12):2627-31; ISSN 0315-162x. (SCI, Impact factor: 3.282；Ranking: 11/22；50%；Score 3x3x5=45)
42.魏正宗. 2003/12. 抗腫瘤壞死因子製劑 臺灣醫界46(12):699-704
43.F Huang, JCC Wei, M Breban. Thalidomide in Ankylosing Spondylitis. Clinical and Experimental Rheumatology. 2002;20(6 supp 28):s-158-61; ISSN 0392-856x. (SCI, Impact factor: 2.364；Ranking: 7/22；32%；Score 3x4x5=60)
44.魏正宗.食物與關節炎的關係. 基層醫訊2001-9.
45.C.T. Chou, Tsai YF, Liu J, J.C.C. Wei, Liao TS, Chen ML, Liu LY. Development of immunomagnetic separation(IMS)-sandwich ELISA for the HLA-B27 antigen detection. J Immunol Methods. 2001;255(1-2):15-22; ISSN 0022-1759. (SCI, Impact factor:2.120；Ranking: 83/121；69%；Score 3x2x5=30)
46.魏正宗. 血清陰性脊椎關節病變.當代醫學2001-8.
47.簡志弘 魏正宗.自體免疫性肝炎. 風濕病雜誌15(1), 29, 2000 Apr
48.James C.C. WEI. Systemic Lupus Erythematosus With Intussusception： A Case Report. Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal. 58(1):58-61, 1996 Ju; ISSN 0366-6999. (SCI, Impact factor: 0.858；Ranking:25/107；23%；Score 3x4x5=60)

大會口頭論文
1.丹參複方食品附加西藥於台灣原發性高血壓病患之有效性與耐受性-十二週之隨機、雙盲、安慰劑控制式臨床試驗 An Eight-week, Randomized, Double-Blind Study to Evaluate the Efficacy and Tolerability of Danshen (Salvia Miltiorrhiza) as Add-on Therapy in Taiwanese Patients with Essential Hypertension. CGCM全球中草藥聯盟年會 2010-8 Hong Kong
2.JCC Wei. Efficacy and immunomodulation of Sterols/Sterolins in patients with allergic rhinitis. A randomized double blind placebo-controlled clinical trial. European Academy of Allergy and Clinical Immunology (EAACI) 2009/6, Warsaw, Poland.
3.JCC Wei. Epidemiological Study from a Large Ankylosing Spondylitis Cohort in Taiwan._APLAR 2008 13th Asia Pacific League of Association for Rheumatology Congress 2008-9, Yokohama, Japan.
4.Chen-Tung Yu, Chien-Wei Liu, Wenlung Li, Chia-Chi Lo, Ching-Sung Wang, James Cheng-Chung Wei. Biomechanical analysis of tibial insert under varus tilt after medial unicompartmental knee arthroplasty .The 2nd International Conference on Bioinformatics and Biomedical Engineering, 2008 May.
5.魏正宗. Traditional Chinese Medicine in the Treatment of Patients with Hyperuricemia. A Double Blind Placebo Controlled Clinical Trial.中國風濕病醫學會2007/12, Kaoshiung
6.JCC Wei. Ankylosing Spondylitis Databank Project in Taiwan. 華夏風濕病醫學會. 2007-12, Hongkong.
7.魏正宗. AGTC-179 in the treatment of patients with rheumatoid arthritis.中國風濕病醫學會2006/12
8.JCC Wei. Traditional Chinese Medicine in the Treatment of Patients with Ankylosing Spondylitis. The 13th International Conference on Oriental medicine (ICOM). 2005/10/20-24. Daegue, Korea.
9.魏正宗. 僵直性脊椎炎之中藥方劑療效評估. 天然藥物國際研討會 2005/6/25國立中國醫藥研究所, 台灣
10.魏正宗. Alefacept in the treatment of patients with psoriasis and psoriatic arthriis.中國風濕病醫學會2004/11.
11.魏正宗. Osteoclastogenesis in Ankylosing Spondylitis. 華夏風濕病醫學會. 2004-11.
12.JCC Wei. Correlation of serological activity and clinical indices in ankylosing spondylitis. 中華民國風濕病醫學會大會. 2003/11.
13.JCC Wei. How to validate BAS indices in ankylosing spondylitis. 中國風濕病醫學會2003/11
14.JCC Wei. THALIDOMIDE FOR SEVERE REFRACTORY ANKYLOSING SPONDYLITIS. An 6 months open trial. 10th Asia Pacific League of Association for Rheumatology Congress 2002-12, Bangkok, Thailand
15.魏正宗. HLA-B61(40) IS STRONGLY ASSOCIATED WITH HLA-B27 NEGATIVE ANKYLOSING SPONDYLITIS PATIENTS IN TAIWAN. 中華民國風濕病醫學會大會2000-11
16.魏正宗. Thalidomide for refractory ankylosing spondylitis. An open trial. 第二屆華夏風濕病醫學會. 2001-11.
17.YF Tsai, Ly Liu, CC Wei, J liu, Th Chang: Development of immunomagnetic separation(IMS)-sandwich ELISA for the HLA-B27 antigen detection. The 15th Joint Annual conference of Biomedical Science(2000).
18.蔡宜芬 魏正宗. THE COMPARISON OF IMMUNOMEGANETIC SEPERATION (IMS)- SANDWICH ELISA AND THE FOW CYTOMETRY METHOD FOR HLA-B27 ANTIGEN DETECIOTN. 中華民國風濕病醫學會大會1999-11
19.魏正宗. USING DYNAMIC MRI TO DETECT EARLY SACROILIITIS. 中華民國風濕病醫學會大會1999-11
20.魏正宗. HLA-B27 subtypes in Chinese with ankylosing spondylitis and normal controls. 中華民國風濕病醫學會大會1998-11
21.魏正宗. SLE with myelodysplastic syndrome: A case report. 中華民國風濕病醫學會大會1998-11
22.簡志弘 魏正宗. Autoimmune hepatitis: A case report. 中華民國風濕病醫學會大會1998-11
23.魏正宗.薦腸關節局部類固醇注射 中華民國風濕病醫學會大會1997-12
24.魏正宗.醫學研究的新助手--網際網路 中華民國風濕病醫學會大會1997-12
25.簡志弘 魏正宗. Psoas muscle abscess: A case report. 中華民國風濕病醫學會大會1996-12
26.魏正宗.網際網路在過敏免疫風濕科之應用 中華民國風濕病醫學會大會1996-12
27.魏正宗.Systemic Lupus Erythematosus With Intussusception： A Case Report. 中華民國風濕病醫學會大會1996-12

壁報論文
1.JCC Wei. Fermented Antrodia Camphorata Mycelia in the Treatment of Patients with Rheumatoid Arthritis. 2010 AIR annual meeting, Taichung.
2.JCC Wei. Hepatitis outcome in patients with rheumatic diseases concomitant with chronic hepatitis treated with biological agents. 2010 AIR annual meeting, Taichung.
3.JCC Wei. Tramadol/Acetaminophen as Add-on Therapy in the Treatment of Patients with Ankylosing Spondylitis. APLAR 2010 14th Asia Pacific League of Association for Rheumatology Congress 2010-8, Hong Kong.
4.魏正宗. Etoricoxib versus Aceclofenac in the Treatment of Patients with Rheumatoid Arthritis中華民國風濕病醫學會大會2008-12
5.James C.C. WEI. Ankylosing spondylitis database project in Taiwan. The Fifth International Congress on Spondyloarthropathy, 2006-10, Belgium
6.James C.C. WEI. Homocysteine Status in Patients with Ankylosing Spondylitis. The Fifth International Congress on Spondyloarthropathy, 2006-10, Belgium
7.James C.C. WEI. Homocysteine status in patients with ankylosing spondylitis. American Academy of Family Physician and WONCA congress, Oct 11-14, 2004, Orlando, USA.
8.James C.C. WEI. C.C. Hsieh. Osteoclastogenesis in patients with ankylosing spondylitis. 11th Asia Pacific League of Association for Rheumatology Congress, Sep 11-15, 2004, Jeju, Korea.
9.James C.C. WEI. HLA-A, B ANTIGENS IN HLA-B27 NEGATIVE ANKYLOSING SPONDYLITIS PATIENTS IN TAIWAN. 2nd International Congress on Spondyloarthropathies. Gent, Belgium, October 4-7, 2000.
10.James C.C. WEI. ENTHESOPATHY PROCEED SYNOVITIS IN SACROILIAC JOINTS OF EARLY ANKYLOSING SPONDYLITIS: EVIDANCE OF DYNAMIC MAGNETIC RESONANCE IMAGING. 9th Asia Pacific League of Association for Rheumatology Congress, May 21-26, 2000, Beijing, China
11.James C.C. WEI. Ankylosing Spondylitis complicated with Japanese B encephalitis after methylprednisolone pulse therapy. Second Asia-Pacific Travel Health Congress, 1998-7, Taipei
12.魏正宗. HLA-B61(40) IS STRONGLY ASSOCIATED WITH HLA-B27 NEGATIVE ANKYLOSING SPONDYLITIS PATIENTS IN TAIWAN. 中華民國風濕病醫學會大會2000-11
13.魏正宗.Ankylosing spondylitis with Sjogren's syndrome and possible SLE: A case report. 中華民國風濕病醫學會大會1999-11
14.James C.C. WEI. HLA-B27 subtypes in Chinese with ankylosing spondylitis and normal controls. The First International Congress on Spondyloarthropathy, 1998-9, Belgium
15.James C.C. WEI. Seroepidemiology of hepatitis A in Taiwan Second Asia-Pacific Travel Health Congress, 1998-7, Taipei

應邀大會演講
1.發炎性背痛之診斷新進展 中華民國風濕病醫學會 2010年12月12日. 台中
2.中醫藥臨床研究與論文發表 2010年10月29日.江蘇省中西醫結合風濕病醫學會/江蘇省中醫風濕病醫學會聯合年會 中國江蘇省無錫市 山明水秀大酒店
3.台灣強直性脊柱炎心理社會關懷模式 2010年10月27日.風濕專科護士培訓班 中國成都市華西醫院
4.臨床試驗的概念與精神 2010年9月12日.中國醫藥大學附設醫院 臨床試驗與醫療發展研討會
5.優良臨床試驗準則 ICH-GCP 2010年9月12日.中國醫藥大學附設醫院 臨床試驗與醫療發展研討會
6.跟臨床研究者攜手的IRB 行政院衛生署中南聯盟研究研討會 2010年9月10日.嘉南療養院
7.2010類風濕性關節炎診斷標準 中華民國風濕病醫學會 2010年9月4日. 新竹.
8.自然醫學臨床試驗之研究設計 世界自然醫學醫學會 2010-8 中國北京
9.Spondyloarthropathies. Early diagnosis and optimal management. APLAR review course, 2009/11, Manila, Philippine
10.Successful Conduct of Clinical Trials. APLAR review course, 2009/11, Manila, Philippine
11.中草藥臨床試驗之研究設計與執行. 海峽兩岸中醫藥發展大會2009/11, Beijing, China.
12.Management of ankylosing spondylitis – A psochosocial support model in Taiwan. 中國四川省風濕病醫學會2009/8, Chengdo, China.
13.風濕性疾病之家族遺傳 中華民國風濕病醫學會2008年12月20日. 台南.
14.臨床試驗的原則與精神2008年3月31日.輔英科技大學附設醫院 優良臨床試驗規範(GCP)研討會
15.臨床試驗的研究設計2008年3月31日.輔英科技大學附設醫院優良臨床試驗規範(GCP)研討會
16.中藥臨床試驗_以高尿酸血症為例2008年3月29日. 中國醫藥大學 國際中醫藥學術研討會
17.臨床研究暨人體試驗委員會訓練課程 2008年3月7日~5月2日.署立彰化醫院
18.中藥臨床試驗之研究設計與執行. 2008年1月4日. 中國醫藥大學中西結合研究所
19.高尿酸血症與痛風的診治. 2007年12月11日. 台中市醫師公會
20.自體免疫疾病治療新進展. 2007年9月12日. 中山醫學大學附設醫院
21.執行臨床試驗應注意事項. 2007年8月31日. 高雄醫學大學臨床試驗研討會
22.臨床試驗的倫理與受試者權益. 2007年8月31日. 高雄醫學大學臨床試驗研討會
23.臨床研究 Clinical research--How to Start ? 2007年8月23日. 署立彰化醫院
24.Efficacy & Tolerability of NSAID & COXIB 2007年8月20日. 沙鹿童醫院內科部
25.常見免疫風濕疾病之診治2007年4月30日. 嘉義陽明醫院
26.僵直性脊椎炎診療新進展. 中華民國風濕病醫學會春季會. 2007年4月21日礁溪
27.非類固醇消炎止痛藥新進展. 2007年3月18日. 台中金典酒店
28.高尿酸血症的中西醫診治與臨床試驗.中華民國中西整合醫學醫學會會員大會. 2007年3月11日. 中國醫藥大學
29.僵直性脊椎炎的中西醫診治. 中華民國中西整合醫學醫學會會員大會. 2007年2月11日. 中國醫藥大學
30.醫師在病友團體之角色.中華民國風濕病醫學會2006年12月15日. 台中.
31.臨床試驗的研究設計與執行. 2006年10月31日. 中山醫學大學附設醫院
32.中藥臨床試驗之倫理與科學. 2006年9月11日. 中國醫藥大學附設醫院
33.中西整合醫學之臨床試驗. 中華民國中西整合醫學醫學會會員大會. 2006年6月11日. 中國醫藥大學
34.僵直性脊椎炎之中藥方劑療效評估 The 20th Symposium on Natural Products. 2005年6月24-25日, 國立中國醫藥研究所(National Research institute of Chinese Medicine).
35.Evidence-Based Medicine in the Treatment of Psoriasis and Psoriatic Arthritis. 風濕病春季醫學會, 2004年5月22日彰化基督教醫院
36.僵直性脊椎炎的臨床與復健的重要性 中華民國風濕病醫學會復健醫學研討會 2002年9月 童綜合醫院.
37.Thalidomide: new indications in the new era. 內科醫學會雲嘉地方月會. 2002年1月嘉義榮民醫院.
38.僵直性脊椎炎. 中華民國風濕病醫學會年會. 2001年11月25日高雄醫學院
39.血清陰性脊椎關節病變. 內科醫學會雲嘉地方月會. 2001年8月大林慈濟醫院
40.下背痛的全方位診斷. 風濕病春季醫學會, 2001年5月26日花蓮慈濟醫院
41.僵直性脊椎炎的新進展. 台灣醫學會春季演講會暨風濕病地方醫學會, 1999年5月15日高雄醫學院
42.關節炎的治療. Arthritis 2000國際醫學會議，1998年10月18日，新加坡國際會議中心

專書
1.Intern Guide魏正宗, 盧致誠. 合記書局, 1987年
2.AS相隨的日子 周昌德, 蔡文展, 魏正宗. 中華民國僵直性脊椎炎關懷協會, 2000年
3.僵直性脊椎炎魏正宗健康世界出版社, 2005年

課程講座
1.內科學/免疫學：僵直性脊椎炎、下背痛、脊椎關節炎、皮肌炎、血管炎、貝氏症、痛風、乾癬、自體免疫疾病。
2.臨床診斷學。
3.臨床試驗的研究設計與執行、中西整合醫學之臨床試驗、臨床研究方法學、中草藥臨床試驗之研究設計與執行。
4.轉譯醫學

主持之研究計畫及臨床試驗
2010.10 FDA GCP SITE INSPECTION PASSED

1.A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK 0663/Etoricoxib in Patients with Rheumatoid Arthritis.
2.A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients with Ankylosing Spondylitis.
3.A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE).
4.A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of apremilast (cc-10004) in subjects with active psoriatic arthritis.
5.A multicentre, 12 week double blind placebo controlled randomized study of etanercept on a background nsaid in the treatment of adult subjects with non radiographic axial spondyloarthritis with a 92 week open label extension.
6.A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy
7.抗腫瘤壞死因子生物製劑治療僵直性脊椎炎登錄計畫
8.IM101075: A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE).
9.丹參複方食品附加西藥於台灣原發性高血壓病患之有效性與耐受性－十二週之隨機、雙盲、安慰劑控制式臨床試驗。An Twelve-week, Randomized, Double-Blind Study to Evaluate the Efficacy and Tolerability of Danshen (Salvia Miltiorrhiza) as Add-on Therapy in Taiwanese Patients with Essential Hypertension
10.A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BlyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE)
11.紅麴加上益生菌對降血脂作用之評估
12.A phase II, randomized, multi-center, double-blind, dose-ranging and placebo-controlled study of STA36 for the treatment of mild-to-moderate and persistent asthma in pediatric patient as an add-on therapy of leukotriene modifiers treatment.
13.Tramadol/ Acetaminophen (Ultracet®)藥劑附加治療於僵直性脊椎炎病患：十二週之隨機、雙盲、安慰劑控制式臨床試驗
14.A Phase IIIB Multicenter, Randomized, Double-Blind-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthritis, Receving Background Methotrexate, and Experiencing an Inadepuate Response to Methotrexate (BMS-RA)
15.A randomized double –blind study to evaluate the safety, pharmacokinetic and pharmacodynamic effects of abetimus sodium in patients with systemic lupus erythematosus (SLE)
16.AGTC-179改善風濕病之隨機雙盲安慰劑控制式之臨床試驗
17.Etanercept versus Adalimumab in the Treatment of Patients with Ankylosing Spondylitis. A Switch Study.
18.Etoricoxib vs Aceclofenac in the treatment of rheumatoid arthritis 比較Etoricoxib與Aceclofenac對類風濕性關節炎患者的療效
19.HealthBaby 裝置與自律神經分析儀之功能比較評估
20.Moducare®治療過敏性鼻炎之隨機雙盲安慰劑對照式臨床試驗
21.MORA生物能共振檢測儀用於過敏病患及自體免疫之臨床試驗
22.OPG基因多型性可能為僵直性脊椎炎的一項易感受因子
23.Rituximab in the treatment of anti-TNF resistant RA. An multi-center open suty in Taiwan一個開放性的試驗以評估MabThera (rituximab)用於治療對一種或多種抗腫瘤壞死因子藥物反應不佳或耐受性不佳的類風濕性關節炎發作病患
24.Tramadol/Acetaminophen (Ultracet®) as add-on therapy in the Treatment of Patients with Ankylosing Spondylitis
25.中藥方劑改善僵直性脊椎炎之先導性試驗
26.中藥方劑改善僵直性脊椎炎之療效評估試驗
27.中藥方劑治療高尿酸血症之先導性試驗-金錢草複方（金錢草、佛手及山楂）
28.中藥方劑治療高尿酸症之先導性臨床試驗(五苓散)
29.內質網壓力反應調節劑對關節病變之治療效應
30.勻采茶對降血脂作用之評估
31.以『自律神經分析儀』探討僵直性脊椎炎與其他免疫疾病病人自律神經功能之研究
32.以Etanercept治療僵直性脊椎炎的多中心開放性研究
33.以高頻熱凝療法治療小面關節症候群
34.以基因微陣列法研究「僵直性脊椎炎」之基因表達
35.以維生素B-6介入探討傳統危險因子CRP、磷酸必哆醛及同伴胱胺酸對造成類風濕性關節炎病人罹患心血關疾病的影響
36.以僵直性脊椎炎病人資料庫研究患者免疫失衡機制
37.加味四妙散及加味佛手散治療高尿酸血症之早期探索性臨床試驗
38.收尋僵直性脊椎炎相關的克雷白氏菌抗原因子
39.免疫奶粉改善過敏性鼻炎症狀之評估
40.免疫調節本複方食品莊松榮精氣新茶飲之隨機雙盲安慰劑控制之臨床試驗
41.抗腫瘤壞死因子(enbrel)對僵直性脊椎炎血清中TLR, BMP, TARIL, MMP及多種Cytokines (TNF, IL18, IL6, IL8, IL10, IL1)等之影響
42.奈米珍珠鈣抗氧化延緩衰老及增進鈣生物利用率
43.非侵入性研究僵直性脊椎炎的基因多型性相關研究
44.建立正常人及僵直性脊椎炎病患資料庫
45.紅球薑粉末膠囊改善過敏體質之早期探索性臨床試驗
46.破骨細胞與內質網壓力在僵直性脊椎炎致病機制中所扮演的角色
47.國際性、多中心研究利用僵直性脊椎炎療效評估標準量表作為脊椎關節炎病患分類標準
48.探討「水解米精與麥精」對於食物過敏患者的安全性
49.細菌感染在僵直性脊椎炎致病機制所扮演的角色
50.喜樂美食品治療高尿酸血症病人之先導性研究
51.善笙紅寶樟芝治療關節炎之早期探索性臨床試驗
52.開放性、多中心臨床試驗以評估台灣慢性乾癬症病患接受每週肌肉注射AMEVIVE一個療程後之療效及安全性

想說的話

魏正宗醫師，現任中山醫學大學附設醫院過敏免疫風濕科主任，中藥臨床試驗中心主任。過去曾任台中榮總、高雄榮總醫師及嘉義榮民醫院家庭醫學科主任，本身也是僵直性脊椎炎的患者。民國八十五年，魏正宗和許多病友共同組成了「中華民國僵直性脊椎炎關懷協會」，並擔任理事長。同時，他也架設了許多相關的網站，多年以來一直致力於僵直性脊椎炎的衛教與研究。

為了研究僵直性脊椎炎，魏正宗在2000及2001年出國進修，到英國皇家國立風濕病醫院(RNHRD)隨知名的僵直性脊椎炎臨床大師Andrei Calin學習僵直性脊椎炎的流行病學研究及臨床評估方法、將BASDAI, BASFI, BAS-G等僵直性脊椎炎臨床評估量表帶回國內。到法國隨Maxime Dougados學習僵直性脊椎炎的藥物臨床試驗、跟Maxime Breban認識HLA-B27基因轉殖大鼠的實驗。2004年獲得藤澤基金會獎學金，到東京大學醫科學研究所免疫風濕科Chikao Morimoto及 Hirotoshi Tanaka教授實驗室參訪研究。2001至2004年間也曾多次至美國UCLA David Yu教授的實驗室學習脊椎炎的microarray實驗及致病機轉的研究。

魏正宗曾經完成台灣首次僵直性脊椎炎的HLA-B27亞型的分析，並在第一屆世界脊椎炎大會發表（J. of Rheumatology. Vol 25, suppl 54: 27, 1998）。2001年與榮總合作完成以免疫磁珠法測量HLA-B27抗原之報告(J. Immunol Methods. 2001;255:15-22)。2003年發表以thalidomide治療僵直性脊椎炎的臨床試驗（Journal of Rheumatology 2003;30(12):2627-31.）。2004年完成HLA-B27陰性之僵直性脊椎炎病人的MHC class I研究，發現HLA-B60及B61基因亦與國人之僵直性脊椎炎有相關（Rheumatology 2004;43:839-42）。

2006年發現僵直性脊椎炎病人的血中同半胱氨酸濃度過高，需補充維他命B群及葉酸。（Clin Rheumatol. 2007 May;26(5):739-42.）2007年完成台灣版僵直性脊椎炎病人評估問卷之信效度評估（Clin Rheumatol 2007; 26:1685–1691）。2007年6月以台灣僵直性脊椎炎資料庫~流行病學、臨床評估量表之信效度、血中發炎指標及HLA基因型分析取得博士學位。2009年發表兩篇重要論文於頂尖醫學雜誌：台灣僵直性脊椎炎病人MMP3/TIMP基因多型性（Annals of the Rheumatic Diseases. 2009;68:1781–6）及RGS1基因用於鑑別診斷脊椎關節炎與機械性下背痛(Arthritis & rheumatism Vol. 60, No. 11, November 2009, 3269–79)。也曾經多次在國內外醫學會發表；薦腸關節局部類固醇注射；以磁振造影診斷早期薦腸關節炎；僵直性脊椎炎病人之破骨細胞培養；僵直性脊椎炎之中藥方劑療效評估等研究；臨床試驗之研究設計等。

魏正宗現為美國風濕病學院(ACR) 院士，美國家庭醫學學院(AAFP) 會員，美國自然醫學會 (ANMA) 會員暨專科醫師，國際僵直性脊椎炎研究組織(ASIF, ASAS)會員。近年來致力於臨床研究，曾任中山醫學大學附設醫院人體試驗委員會主任委員，並通過美國臨床研究專業協會(ACRP)認證會員(Certified Physician Investigator)。

目前，魏正宗致力於僵直性脊椎炎、乾癬、痛風、過敏的轉譯醫學與臨床研究，過去五年共執行約三十件跨國或學術臨床試驗，並推廣中西整合與自然醫學，擔任中山醫學大學附設醫院過敏免疫風濕科主任、中藥臨床試驗中心主任及中草藥暨保健食品研究群執行長，執行過敏及免疫疾病之西藥、中草藥及保健食品臨床試驗。